SOURCE: CLX Investment Company, Inc.

March 20, 2008 09:01 ET

CLX Investment Company Announces Pre-Clinical Trials Validation Study on Zonda's Rapid Point of Care Test for Chlamydia

Study Will Be Used to Perfect Clinical Trials Protocol

MURRIETA, CA--(Marketwire - March 20, 2008) - CLX Investment Company, Inc. (OTCBB: CLXN), which owns 51% of Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests for the medical and non-medical markets, today announced that the company is preparing to begin a validation study for Zonda's rapid point of care test for chlamydia in preparation for upcoming clinical trials.

Safis Solutions is currently interviewing virology laboratories as candidates to conduct the study, which is expected to begin shortly. The purpose of the study is to perfect the testing protocol in preparation for the clinical trials as part of the process to achieve FDA clearance for the product.

"We are taking all of the steps necessary to ensure that our clinical trials are done correctly and that we maintain the highest level of integrity throughout this process," stated Vera Leonard, chief executive officer of Zonda and CLX. "The market potential of Zonda's rapid point of care test for chlamydia, assuming it receives FDA clearance and CLIA waiver, is so significant that we want to make certain that all of our procedures are conducted correctly.

"There is no lack of confidence in the product by management, and we look forward to beginning both the validation study and, shortly thereafter, the clinical trials," Ms. Leonard added.

In addition to their use in preparation for the clinical trials, results from the validation study may be helpful in other applications, such as in overseas markets where additional clinical data can support the sales of the products currently in the market. CLX may also pursue a strategic alliance relationship with an established company in the U.S. medical diagnostic testing market to provide resources and assistance through the clinical trials and FDA clearance application process, and the validation study may help to secure such a relationship.

Safis Solutions is assisting Zonda in the process of selecting a laboratory for the validation study. Safis Solutions (www.safis-solutions.com), an Indianapolis-based regulatory compliance consulting company serving pharmaceutical, medical device and biotech companies worldwide, has been retained as a sub-contractor of American Health Partners, LLC (AHP), which has been engaged by CLX to assist with the launch of medical diagnostic testing products in its subsidiary operations. Safis Solutions is providing ongoing consulting services in the areas of regulatory approvals and quality systems for Zonda and additional potential future medical diagnostic technologies acquired by CLX.

To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.php.

About CLX Investment Company

CLX Investment Company (www.clxinvestments.com) holds a 51% equity interest in Zonda, Inc. CLX has also invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact Information

  • Contact:
    Gemini Financial Communications
    A. Beyer
    951-677-8073
    Email Contact